Vertex Pharmaceuticals Incorporated Common Stock Quote & Summary Data
Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don’t know the stock symbol? Use the Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.
“Best Ask” is the lowest price currently being asked for a block of stock.
Prices during the When Issued trading period are used in the 52 week high/low calculation.
ETFs with VRTX as a Top 10 Holding*
Company Description (as filed with the SEC)
We are in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. We use precision medicine approaches with the goal of creating transformative drugs for patients in specialty markets. Our business is focused on developing and commercializing therapies for the treatment of cystic fibrosis, or CF, and advancing our research and development programs in other indications, while maintaining our financial strength. Cystic Fibrosis Our two marketed medicines are ORKAMBI and KALYDECO, which together are approved to treat approximately 40% of the 75,000 CF patients in North America, Europe and Australia. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for approximately 25,000 patients who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator, or CFTR, gene. . More .
Where does VRTX fit in the risk graph?